Ervice providerPerspectiveDirectUSD3DCRTSBRTIMRTCountry Sort of studyLanni et al. (2011) USAReferenceCost-effectivenessRFARFA: 44,Bijlani et

Ervice providerPerspectiveDirectUSD3DCRTSBRTIMRTCountry Sort of studyLanni et al. (2011) USAReferenceCost-effectivenessRFARFA: 44,Bijlani et al.frontiersin.org Procedures compared Cost-utility IMRT PT Societal: SBRT: 25,097; IMRT: 35,088; PT: 71,339 Cost-utility IMRT Cost-utility alone Gemcitabine plus…